We then compare the mutational signatures between patients with DCB and patients with no durable benefit (NDB) after immunotherapy based on recently published NSCLC anti-PD-1 immune checkpoint blockade therapy dataset [20]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.